PL2229148T3 - Sposób otrzymywania krystalicznych cząstek stałych substancji leczniczej - Google Patents

Sposób otrzymywania krystalicznych cząstek stałych substancji leczniczej

Info

Publication number
PL2229148T3
PL2229148T3 PL08859412T PL08859412T PL2229148T3 PL 2229148 T3 PL2229148 T3 PL 2229148T3 PL 08859412 T PL08859412 T PL 08859412T PL 08859412 T PL08859412 T PL 08859412T PL 2229148 T3 PL2229148 T3 PL 2229148T3
Authority
PL
Poland
Prior art keywords
particulate
preparing
drug substance
crystalline drug
crystalline
Prior art date
Application number
PL08859412T
Other languages
English (en)
Polish (pl)
Inventor
Gerhard Muhrer
Thomas Kieckbusch
Dilraj Singh
Ranjit Thakur
Kurt Schaffluetzel
Norbert Rasenack
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39387173&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2229148(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2229148T3 publication Critical patent/PL2229148T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
PL08859412T 2007-12-13 2008-12-11 Sposób otrzymywania krystalicznych cząstek stałych substancji leczniczej PL2229148T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07123165 2007-12-13
EP08859412.2A EP2229148B1 (en) 2007-12-13 2008-12-11 Process for preparing a particulate and crystalline drug substance
PCT/EP2008/067364 WO2009074666A1 (en) 2007-12-13 2008-12-11 Organic compounds

Publications (1)

Publication Number Publication Date
PL2229148T3 true PL2229148T3 (pl) 2014-08-29

Family

ID=39387173

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08859412T PL2229148T3 (pl) 2007-12-13 2008-12-11 Sposób otrzymywania krystalicznych cząstek stałych substancji leczniczej

Country Status (13)

Country Link
US (1) US20100266696A1 (cg-RX-API-DMAC7.html)
EP (1) EP2229148B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011506400A (cg-RX-API-DMAC7.html)
KR (1) KR20100095587A (cg-RX-API-DMAC7.html)
CN (1) CN101896165B (cg-RX-API-DMAC7.html)
AU (1) AU2008334547B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0820745A2 (cg-RX-API-DMAC7.html)
CA (1) CA2707594C (cg-RX-API-DMAC7.html)
ES (1) ES2460576T3 (cg-RX-API-DMAC7.html)
PL (1) PL2229148T3 (cg-RX-API-DMAC7.html)
PT (1) PT2229148E (cg-RX-API-DMAC7.html)
RU (1) RU2496479C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009074666A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469630B2 (en) 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
CN103501791B (zh) * 2011-05-03 2016-05-18 奇斯药制品公司 用于通过吸入给药的改良皮质类固醇悬浮制剂
GB201307659D0 (en) 2013-04-26 2013-06-12 Korea Coast Guard Commissioner Preparation of drug particles by micronisation
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PT107433B (pt) * 2014-01-28 2018-12-04 Hovione Farm S A Processo de redução e controlo do tamanho de partícula
HRP20260435T1 (hr) 2014-09-09 2026-05-08 Vectura Limited Formulacija koja sadrži glikopirolat, postupak i uređaj
CN106749008A (zh) * 2015-11-23 2017-05-31 北京九和药业有限公司 一种马来酸茚达特罗的微粉化方法及其应用
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
ES2805434T3 (es) 2016-07-29 2021-02-12 Inke Sa Procedimiento de estabilización de tamaño de partícula
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
US20240293317A1 (en) * 2020-04-20 2024-09-05 Board Of Regents, The University Of Texas System Lipid nanoparticle (lnp) delivery systems and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
EP2283817B1 (en) * 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
CA2559915C (en) * 2004-03-23 2013-07-02 Novartis Ag Micronization of pharmaceutically active agents
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
CN101102740A (zh) * 2005-01-07 2008-01-09 卫材R&D管理有限公司 药用组合物以及其制备方法
EP2484382A1 (en) * 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
RU2008108176A (ru) * 2005-08-26 2009-10-10 Астразенека Аб (Se) Комбинация соединений, которая может быть применена в лечении респеративных заболеваний, особенно хронического обструктивного заболевания легких (copd) и астмы
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations

Also Published As

Publication number Publication date
RU2496479C2 (ru) 2013-10-27
CA2707594A1 (en) 2009-06-18
BRPI0820745A2 (pt) 2015-06-16
EP2229148A1 (en) 2010-09-22
KR20100095587A (ko) 2010-08-31
EP2229148B1 (en) 2014-03-05
ES2460576T3 (es) 2014-05-13
CN101896165A (zh) 2010-11-24
WO2009074666A1 (en) 2009-06-18
CA2707594C (en) 2015-08-18
AU2008334547A1 (en) 2009-06-18
RU2010128248A (ru) 2012-01-20
PT2229148E (pt) 2014-05-26
US20100266696A1 (en) 2010-10-21
AU2008334547B2 (en) 2011-06-30
CN101896165B (zh) 2013-07-17
JP2011506400A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
PT2229148E (pt) Processo para preparação de uma substância farmacológica particulada e substancialmente cristalina
IL205759A (en) History of isoxazolo-pyridine, a process for their preparation and the drugs containing them
EP2185159A4 (en) BORTEZOMIB AND MANUFACTURING METHOD THEREFOR
ZA201102760B (en) Process for preparing chlorins and their pharmaceutical uses
EP2046751A4 (en) PROCESS FOR PRODUCING SOLIFENACIN AND ITS SALTS
ZA201002723B (en) Indolinone derivatives and process for their manufacture
IL212639A0 (en) Piperazine salt and a process for the preparation thereof
IL181607A0 (en) Novel process for preparing montelukast and salts thereof
PL2213654T3 (pl) Sposób wytwarzania pochodnych 2-amino-5-bromobenzamidu
IL199124A (en) A process for preparing fluoromethyl-converted heterocyclic compounds
ZA201101005B (en) A process for preparing a particulate filter
ZA200806799B (en) Novel pyrone-indole derivatives and process for their preparation
EP2318479A4 (en) METHOD AND SYSTEMS FOR THE PRODUCTION OF MATERIALS FOR SUCRALOSEPRODUCTION
GB0704335D0 (en) Process for preparing an encapsulated particulate solid
IL188512A0 (en) Process for preparing malathion for pharmaceutical use
ZA200808308B (en) Process for preparing linezolid
GB0719248D0 (en) Compounds and methods for pharmaceutical use
ZA201201517B (en) A particulate fluorescer and a process for preparing the same
GB0614133D0 (en) Process for preparing a pharmaceutical compound
PL2274303T3 (pl) Sposoby otrzymywania sunitynibu i jego soli
EP2181109A4 (en) CRYSTALLINE PARTICLES OF EPROSARTAN MESYLATE AND PROCESS FOR PREPARING PURE EPROSARTAN
GB0716298D0 (en) Process for pharmaceutical compound
IL196719A0 (en) Process for preparing amorphous lercanidipine hydrochloride
ZA200907810B (en) Process for preparing valsartan
EP2114883A4 (en) PROCESS FOR THE PREPARATION OF LERCANIDIPINE HYDROCHLORIDE